Dr. Reddy Plans the Onset of P-III trial for DRL_RI (biosimilar- rituximab) in the Korea
Shots:
- The P-III trial involves assessing of DRL_RI vs Roche’s MabThera (rituximab) in 284 patients including 26 Koreans- with stage II-IV- CD20 positive- and follicular lymphoma previously treated have low tumor burden- evaluating its efficacy- safety- and immunogenicity
- Dr. Reddy’s plan to evaluate DRL_RI in Korea while Paraxel to provide clinical research services and Korea’s MFDS has also approved P-III trial for DRL_RI on Wednesday
- DRL_RI is a mAb and a biosimilar of Roche’s MabThera and will be targeted for lymphoma- chronic lymphocytic leukemia- rheumatoid arthritis- granulomatosis with polyangiitis and microscopic polyangiitis
Click here to read full press release/ article | Ref: KoreaBioMed | Image: Twitter
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com